...
首页> 外文期刊>BMC Cancer >Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis
【24h】

Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis

机译:血管周血管侵犯和NHERF1表达定义了与不良预后相关的2级浸润性乳腺癌的免疫表型

获取原文

摘要

Background Traditional determinants proven to be of prognostic importance in breast cancer include the TNM staging, histological grade, proliferative activity, hormone receptor status and HER2 overexpression. One of the limitations of the histological grading scheme is that a high percentage of breast cancers are still classified as grade 2, a category with ambiguous clinical significance. The aim of this study was to best characterize tumors scored as grade 2. Methods We investigated traditional prognostic factors and a panel of tumor markers not used in routine diagnosis, such as NHERF1, VEGFR1, HIF-1α and TWIST1, in 187 primary invasive breast cancers by immunohistochemistry, stratifying patients into good and poor prognostic groups by the Nottingham Prognostic Index. Results Grade 2 subgroup analysis showed that the PVI (p = 0.023) and the loss of membranous NHERF1 (p = 0.028) were adverse prognostic factors. Relevantly, 72% of grade 2 tumors were associated to PVI+/membranous NHERF1- expression phenotype, characterizing an adverse prognosis (p = 0.000). Multivariate logistic regression analysis in the whole series revealed poor prognosis correlated with PVI and MIB1 (p = 0.000 and p = 0.001, respectively). Furthermore, in the whole series of breast cancers we found cytoplasmic NHERF1 expression positively correlated to VEGFR1 ( r = 0.382, p = 0.000), and in VEGFR1-overexpressing tumors the oncogenic receptor co-localized with NHERF1 at cytoplasmic level. Conclusions The PVI+/membranous NHERF1- expression phenotype identifies a category of grade 2 tumors with the worst prognosis, including patient subgroup with a family history of breast cancer. These observations support the idea of the PVI+/membranous NHERF1- expression immunophenotype as a useful marker, which could improve the accuracy of predicting clinical outcome in grade 2 tumors.
机译:背景被证明在乳腺癌中具有预后意义的传统决定因素包括TNM分期,组织学等级,增殖活性,激素受体状态和HER2过表达。组织学分级方案的局限性之一是仍然有很高比例的乳腺癌被归为2级,这是具有模糊临床意义的一类。这项研究的目的是最好地鉴定2级肿瘤。方法我们调查了187例原发性浸润性乳腺癌的传统预后因素和一组常规诊断中未使用的肿瘤标志物,例如NHERF1,VEGFR1,HIF-1α和TWIST1。免疫组织化学检测癌症,根据诺丁汉预后指数将患者分为好和坏预后组。结果2级亚组分析显示PVI(p = 0.023)和膜性NHERF1丢失(p = 0.028)是不良预后因素。与此相关的是,72%的2级肿瘤与PVI + /膜NHERF1表达表型有关,预后不良(p = 0.000)。整个系列的多因素logistic回归分析显示与PVI和MIB1相关的不良预后(分别为p = 0.000和p = 0.001)。此外,在整个乳腺癌系列中,我们发现细胞质NHERF1表达与VEGFR1正相关(r = 0.382,p = 0.000),而在VEGFR1过表达的肿瘤中,致癌受体与NHERF1在细胞质水平共定位。结论PVI + /膜NHERF1表达表型可确定一类预后最差的2级肿瘤,包括具有乳腺癌家族史的患者亚组。这些观察结果支持PVI + /膜NHERF1表达免疫表型作为有用标记的想法,可以提高预测2级肿瘤临床预后的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号